Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis–associated pulmonary arterial hypertension: a multicenter, double-blind …
RT Zamanian, D Badesch, L Chung… - American journal of …, 2021 - atsjournals.org
Rationale: Systemic sclerosis (SSc)–pulmonary arterial hypertension (PAH) is one of the
most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis …
most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis …
Infection and pulmonary vascular diseases consortium: United against a global health challenge
SD Oliveira, S Almodóvar, G Butrous… - Pulmonary …, 2024 - Wiley Online Library
Leveraging the potential of virtual platforms in the post‐COVID‐19 era, the Infection and
Pulmonary Vascular Diseases Consortium (iPVDc), with the support of the Pulmonary …
Pulmonary Vascular Diseases Consortium (iPVDc), with the support of the Pulmonary …
The landscape of noncoding RNA in pulmonary hypertension
The transcriptome of pulmonary hypertension (PH) is complex and highly genetically
heterogeneous, with noncoding RNA transcripts playing crucial roles. The majority of RNAs …
heterogeneous, with noncoding RNA transcripts playing crucial roles. The majority of RNAs …
Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension
P Chelladurai, C Kuenne, A Bourgeois… - Science Translational …, 2022 - science.org
Phenotypic alterations in resident vascular cells contribute to the vascular remodeling
process in diseases such as pulmonary (arterial) hypertension [P (A) H]. How the molecular …
process in diseases such as pulmonary (arterial) hypertension [P (A) H]. How the molecular …